Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

laboratorija sovremennogo zdorovja - kapsula

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imūnsupresanti - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 un 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 un 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

košļājamā tablete

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

acm laboratorie dermatologique - kapsula

Latvija - latviešu - Zāļu valsts aģentūra

meda pharma gmbh & co.kg, germany - salbutamols - inhalācijas pulveris - 100 µg/devā

Latvija - latviešu - Zāļu valsts aģentūra

meda pharma, sia, latvija - formoterola fumarāta dihidrāts - inhalācijas pulveris - 12 mikrogrami/izsmidzinājumā

Latvija - latviešu - Zāļu valsts aģentūra

meda pharma, sia, latvija - formoterola fumarāta dihidrāts - inhalācijas pulveris - 6 mikrogrami/izsmidzinājumā

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - diklofenaka nātrija sāls - zarnās šķīstošā tablete - 50 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - diklofenaka dietilamīna sāls - gels - 11,6 mg/g